Hindryckx et al. [3] have suggested that there is a slightly increased risk of opportunistic infections in patients treated with anti-TNF-α agents compared with patients treated with vedolizumab or ustekinumab, which has not been demonstrated in clinical trials in CD patients. This evidence concerns the gene TNF and Opportunistic infection.